Adjuvant therapy for gastric cancer: Current and future directions

Table 4 Trials of adjuvant chemo-radiotherapy vs adjuvant chemotherapy in gastric cancer after 2006

Ref.	Year		Postop CRT arms	No. of patients	% having D2 dissection	Survival Outcome	P value	Outcome	P value
Lee et al[37]	2012	Surg	Cape/Cis x2 - 45Gy/Cape - Cape/Cis x2	458	100%			3-yr DFS 78.2% vs 74.2%	0.862
		Surg	Cape/Cis - x6
Yu et al[42]	2012	Surg	FU/LV - 45Gy/FU/LV - FU/LV	404	100%	5-yr OS 48% vs 41.8	0.122 (for median OS)	5-yr RFS 45.2% vs 35.8%	0.029 (for median OS)
		Surg	FU/LV
Kim et al[39]	2012	Surg	5-FU/LV x5	90	100%	54.6% vs 65.2%	0.67
		Surg	x1 5-FU/LV - 45Gy/5-FU - x2 5-FU/LV
Bamias et al[40]	2010	Surg	Docetaxel/Cisplatin x6	147	44% D1-2	OS/DFS no difference
		Surg	Docetaxel/Carboplatin + 45Gy
Yu et al[42]	2012	Surg	5-FU/LV x5	68	69%	3yr OS 68% vs 44%	< 0.05	3-yr DFS 56% vs 29%	< 0.05
		Surg	INT-0116
Kwon et al[41]	2010	Surg	5-FU/Cis x6	61	100%	5-yr OS 70.1 vs 70%	0.814	5-yr DFS 80% vs 75%	0.887
		Surg	FPx1 - 45Gy/Cape - FP x3

Cape: Capecitabine; Cis: Cisplatin; FU/LV: Fluorouracil/leucovorin; FP: Fluorouracil/cisplatin; OS: Overall survival; DFS: Disease-free survival; RFS: Relapse-free survival.